Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from ...

BOSTON — Gov. Maura Healey has ordered inspections of state-run homeless shelters after a 28-year-old migrant was arrested at a Revere hotel with a banned ‘assault’ rifle and a stash of ...

BOSTON — Gov. Maura Healey signed a pair of bills Wednesday aimed at lowering prescription drug costs and improving the state’s oversight of hospitals in response to Steward Health Care System ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Governor Maura Healey is requesting a moment of silence on Thursday morning to honor the life of former President Jimmy Carter, who died late last month. President Joe Biden declared Jan. 9 a ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

The trial was part of the HEALEY ALS Platform Trial initiative currently testing multiple drugs against this disease. The 24-week trial showed that fosigotifator did not meet its primary or ...